Literature DB >> 1605618

Comparison of antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B cholesteryl sulfate colloidal dispersion.

L H Hanson1, D A Stevens.   

Abstract

Complexing amphotericin B (AmB) with lipids or entrapping it in liposomes may increase its efficacy by reducing toxicity and affecting distribution. However, depending on the lipids involved, interference with antifungal activity has been shown. We compared the in vitro activity of AmB colloidal dispersion by cholesteryl sulfate (ABCD) to the standard AmB deoxycholate suspension (ABDS) against 41 isolates of 15 pathogenic species. Broth dilution MIC and minimum fungicidal concentration (MFC) ranges were similar, and the same number of isolates had lower MICs and MFCs with one drug as with the other. Differences between species were noted. In less than a third of comparisons, there were large (fourfold or more) decreases in ABCD activity relative to that of ABDS, and in approximately 1/10, there were large increases. Thus, ABCD complexing variably affects AmB activity. As ABCD pharmacokinetics and toxicology differ from those of ABDS, the significance of these results for in vivo activity needs to be determined.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1605618      PMCID: PMC188465          DOI: 10.1128/AAC.36.2.486

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Comparative in vitro effects of liposomal amphotericin B, amphotericin B-deoxycholate, and free amphotericin B against fungal strains determined by using MIC and minimal lethal concentration susceptibility studies and time-kill curves.

Authors:  E D Ralph; A M Khazindar; K R Barber; C W Grant
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

2.  Obfuscation of the activity of antifungal antimicrobics by culture media.

Authors:  P D Hoeprich; P D Finn
Journal:  J Infect Dis       Date:  1972-10       Impact factor: 5.226

3.  Amphotericin B toxicity. A follow-up report of 53 patients.

Authors:  R P Miller; J H Bates
Journal:  Ann Intern Med       Date:  1969-12       Impact factor: 25.391

Review 4.  Liposome-encapsulated amphotericin B: a promising new treatment for disseminated fungal infections.

Authors:  V J Wiebe; M W DeGregorio
Journal:  Rev Infect Dis       Date:  1988 Nov-Dec

5.  Growth of Paracoccidioides brasiliensis yeast phase in a chemically defined culture medium.

Authors:  A Restrepo; B E Jiménez
Journal:  J Clin Microbiol       Date:  1980-08       Impact factor: 5.948

6.  Evaluation of cilofungin, a lipopeptide antifungal agent, in vitro against fungi isolated from clinical specimens.

Authors:  L H Hanson; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

7.  In vitro antifungal activities of amphotericin B and liposome-encapsulated amphotericin B.

Authors:  R L Hopfer; K Mills; R Mehta; G Lopez-Berestein; V Fainstein; R L Juliano
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

8.  Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats.

Authors:  R M Fielding; P C Smith; L H Wang; J Porter; L S Guo
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

9.  Comparative efficacy of amphotericin B colloidal dispersion and amphotericin B deoxycholate suspension in treatment of murine coccidioidomycosis.

Authors:  K V Clemons; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

10.  Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B.

Authors:  F C Szoka; D Milholland; M Barza
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

  10 in total
  22 in total

Review 1.  Antifungal agents: chemotherapeutic targets and immunologic strategies.

Authors:  N H Georgopapadakou; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

2.  In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important?

Authors:  C E Swenson; W R Perkins; P Roberts; I Ahmad; R Stevens; D A Stevens; A S Janoff
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

Review 3.  Carrier effects on biological activity of amphotericin B.

Authors:  J Brajtburg; J Bolard
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

Review 4.  Lipid formulations of amphotericin B. Less toxicity but at what economic cost?

Authors:  J Tollemar; O Ringdén
Journal:  Drug Saf       Date:  1995-10       Impact factor: 5.606

5.  Ocular distribution of intravenously administered lipid formulations of amphotericin B in a rabbit model.

Authors:  David Goldblum; Kaspar Rohrer; Beatrice E Frueh; Regula Theurillat; Wolfgang Thormann; Stefan Zimmerli
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

6.  Efficacy of intravenous liposomal amphotericin B (AmBisome) against coccidioidal meningitis in rabbits.

Authors:  Karl V Clemons; Raymond A Sobel; Paul L Williams; Demosthenes Pappagianis; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

7.  Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations.

Authors:  E M Johnson; J O Ojwang; A Szekely; T L Wallace; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

8.  Treatment of murine candidiasis and cryptococcosis with amphotericin B incorporated into egg lecithin-bile salt mixed micelles.

Authors:  J Brajtburg; S Elberg; S J Travis; G S Kobayashi
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

Review 9.  The Mechanistic Targets of Antifungal Agents: An Overview.

Authors:  Tryphon K Mazu; Barbara A Bricker; Hernan Flores-Rozas; Seth Y Ablordeppey
Journal:  Mini Rev Med Chem       Date:  2016       Impact factor: 3.862

10.  Different components in human serum inhibit multiplication of Cryptococcus neoformans and enhance fluconazole activity.

Authors:  F Nassar; E Brummer; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.